CTSO - CONSENSUS CO - Cytosorbents

Cytosorbents (CTSO) develops automated blood filtration cartridges, where real-time digital flow control minimizes the risk of human error. The company's price history shows a current level of 47.66. Management is currently focused on implementing these systems in emergency medicine and obtaining US licenses to expand the therapeutic capabilities of its devices.

FDA approval delays and the rapid depletion of liquidity at Cytosorbents (CTSO) create serious fundamental risks for the business's capitalization. Analyzing the analyst consensus chart for the stock, an investor can see the weighted average target price calculated via discounted cash flow (DCF), which allows for the real-time tracking of the asset's revaluation amid rising interest expenses and revenue uncertainty.